Introduction Massive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients with CF and haemoptysis after BAE using coils. Methods We carried out a retrospective cohort study of 34 adult patients treated for massive haemoptysis with super selective bronchial artery coil embolisation (ssBACE) between January 2008 and February 2015. Embolisation protocol was restricted to the culprit vessel(s) and three lobes maximum. Demographic data, functional end-expiratory volume in 1 s in % predicted (FEV1% pred.) and body mass index before and after ssBACE, sputum colonisation, procedural data, time to transplant and time to death were documented. Results Patients treated with ssBACE showed significant improvement of FEV1% pred. after embolisation (p=0.004) with 72.8% alive 5 years post-ssBACE. Mean age of the patients was 29.9 years (±7.7). Mean FEV1% pred. was 45.7% (±20.1). Median survival to follow-up was 75 months (0–125). Severe complication rate was 0%, recanalisation rate 8.8% and 5-year-reintervention rate 58.8%. Chronic infection with Pseudomonas aeruginosa was found in 79.4%, Staphylococcus areus in 50% and Aspergillus fumigatus in 47.1%. Discussion ssBACE is a safe and effective treatment for massive haemoptysis in patients with CF with good results for controlling haemostasis and excellent short-term and long-term survival, especially in severely affected patients with FEV<40% pred. We think the data of our study support the use of coils and a protocol of careful and prudent embolisation. All data relevant to the study are included in the article or uploaded as supplemental information.

中文翻译：

---

囊性纤维化患者大量咯血的线圈栓塞术

简介 大咯血是晚期囊性纤维化 (CF) 肺病中危及生命的事件，支气管动脉栓塞 (BAE) 作为护理治疗的标准。我们研究的目的是使用线圈仔细检查 CF 和咯血患者在 BAE 后的短期和长期结果。方法 我们对 2008 年 1 月至 2015 年 2 月期间接受超选择性支气管动脉线圈栓塞 (ssBACE) 治疗的 34 名成人大咯血患者进行了一项回顾性队列研究。栓塞方案仅限于罪犯血管和最多三个肺叶。记录人口统计学数据、1 s 功能性呼气末容积（预测的 FEV1%）和 ssBACE 前后的体重指数、痰定植、手术数据、移植时间和死亡时间。结果 接受 ssBACE 治疗的患者的 FEV1% pred 显着改善。栓塞后 (p=0.004)，ssBACE 后 5 年存活率为 72.8%。患者的平均年龄为 29.9 岁 (±7.7)。平均 FEV1% 预测。为 45.7% (±20.1)。随访的中位生存期为 75 个月 (0-125)。严重并发症率为 0%，再通率为 8.8%，5 年再干预率为 58.8%。铜绿假单胞菌慢性感染率为 79.4%，金黄色葡萄球菌为 50%，烟曲霉为 47.1%。讨论 ssBACE 是一种安全有效的治疗 CF 患者大咯血的方法，具有良好的止血控制效果和优异的短期和长期生存率，尤其是在 FEV<40% pred 的严重受影响患者中。我们认为我们的研究数据支持使用线圈和谨慎谨慎的栓塞方案。与研究相关的所有数据都包含在文章中或作为补充信息上传。